OncoCyte Q4 EPS $(2.18) Misses $(1.14) Estimate, Sales $314.00K Miss $316.67K Estimate
Portfolio Pulse from Benzinga Newsdesk
OncoCyte (NASDAQ:OCX) reported Q4 earnings with a per-share loss of $(2.18), missing the consensus estimate of $(1.14) by 91.23%. Quarterly sales were $314.00K, falling short of the $320.00K estimate by 1.88%.
April 12, 2024 | 10:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
OncoCyte reported a significant miss in Q4 EPS and slight miss in sales, with losses per share at $(2.18) vs. an $(1.14) estimate and sales at $314K vs. $320K expected.
The significant miss in both EPS and sales for OncoCyte suggests a negative short-term impact on the stock. Missing earnings estimates, especially by such a large margin, typically leads to negative investor sentiment and could result in a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100